Basic information Safety Related Supplier

ChemicalBook Product Catalog TRC051384 HCl

1/1

TRC051384 HCl NEW

$64.00 5mg

$119.00 10mg

$216.00 25mg

Min. Order
Purity98.29%
Cas No1333327-56-2
Supply Ability10g
Update time2025-11-10

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	TRC051384 HCl
CAS No	1333327-56-2
EC-No
Min. Order
Purity	98.29%
Supply Ability	10g
Release date	2025/11/10

Product Introduction

Bioactivity

Name	TRC051384 HCl
Description	TRC051384 is an inducer of heat shock protein Hsp70, activating heat shock factor-1 and enhancing Hsp72 expression in neurons and glial cells.
Animal Research	Focal cerebral ischemia was produced in rats by occluding the MCA using the intra luminal suture technique.?Rats subjected to 2 hours focal cerebral ischemia were administered by intra-peritoneal route, TRC051384 or vehicle every 2 hours for 48 hours, from 4th hour or 8th hour after onset of ischemia.?Progression of infarct and edema was assessed up to 48 hours post ischemic insult using magnetic resonance imaging and the neurological disability and survival studied till 7 days.
In vivo	TRC051384, a novel compound belonging to substituted 2-propen-1-one class is a potent inducer of heat shock protein 70 (HSP70).Treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia.?Significant improvement in survival (50% by day 2 and 67.3% by day 7) was observed with TRC051384 treatment initiated at 4 hours after ischemia onset.?Induction of HSP70 by TRC051384 involves HSF1 activation and results in elevated chaperone and anti-inflammatory activity.?These results show that TRC051384 has the potential to be developed as a novel pharmacological agent for the treatment of ischemic stroke.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 60 mg/mL (119.52 mM), Sonication is recommended.
Keywords	TRC-051384 \| TRC051384 \| TRC 051384 \| Hsp70
Inhibitors Related	Ethoxyquin \| SNX0723 \| Tamoxifen \| SNX2112 \| Ganetespib \| Teprenone \| Elesclomol \| Rifabutin \| Palmitic acid \| Paeoniflorin \| Tamoxifen Citrate \| 17-AEP-GA
Related Compound Libraries	Cuproptosis Compound Library \| Bioactive Compound Library \| Membrane Protein-targeted Compound Library \| Anti-Breast Cancer Compound Library \| NO PAINS Compound Library \| Metabolism Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Compound Library

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book